Business Description
Astellas Pharma Inc
ISIN : JP3942400007
Description
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.33 | |||||
Equity-to-Asset | 0.45 | |||||
Debt-to-Equity | 0.58 | |||||
Debt-to-EBITDA | 5.32 | |||||
Interest Coverage | 1.27 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 1.64 | |||||
Beneish M-Score | -2.84 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.3 | |||||
3-Year EBITDA Growth Rate | -6.9 | |||||
3-Year EPS without NRI Growth Rate | -19.6 | |||||
3-Year FCF Growth Rate | 19.5 | |||||
3-Year Book Growth Rate | 6.5 | |||||
Future 3-5Y Total Revenue Growth Rate | 5.2 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
6-1 Month Momentum % | -22.64 | |||||
12-1 Month Momentum % | -22.64 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.91 | |||||
Quick Ratio | 0.71 | |||||
Cash Ratio | 0.25 | |||||
Days Inventory | 253.45 | |||||
Days Sales Outstanding | 110 | |||||
Days Payable | 184.25 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Dividend Growth Rate | 14.5 | |||||
3-Year Average Share Buyback Ratio | 1.1 | |||||
Shareholder Yield % | 7.1 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 81.76 | |||||
Operating Margin % | 0.81 | |||||
FCF Margin % | 8.67 | |||||
ROC (Joel Greenblatt) % | 10.57 | |||||
ROCE % | 1.58 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 4041.67 | |||||
Shiller PE Ratio | 17.61 | |||||
PS Ratio | 1.7 | |||||
PB Ratio | 1.74 | |||||
Price-to-Free-Cash-Flow | 21.11 | |||||
Price-to-Operating-Cash-Flow | 12.22 | |||||
EV-to-EBIT | 101.4 | |||||
EV-to-Forward-EBIT | 11.4 | |||||
EV-to-EBITDA | 19.51 | |||||
EV-to-Forward-EBITDA | 9.11 | |||||
EV-to-Revenue | 2.07 | |||||
EV-to-Forward-Revenue | 2.31 | |||||
EV-to-FCF | 25.48 | |||||
Price-to-Projected-FCF | 0.86 | |||||
Price-to-Median-PS-Value | 0.66 | |||||
Earnings Yield (Greenblatt) % | 0.99 | |||||
FCF Yield % | 4.81 | |||||
Forward Rate of Return (Yacktman) % | -1.14 |